title: Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis.
abstract: In this study, the levels of fibronectin, vitronectin, leptin, tissue plasminogen activator (t-PA), and lipid parameters were investigated in patients with coronary artery disease (CAD) and control group. The average plasma fibronectin levels in CAD patients group were significantly higher compared with the control group (p=0.006). Moreover, in patients with triple-vessel disease, plasma fibronectin levels were found to be significantly higher than those in the control group (p<0.05). Plasma vitronectin levels in patients with CAD were found to be significantly higher than those in the control group (p=0.000). In addition, in patients with double vessel disease plasma vitronectin levels were significantly higher than no vessel disease and control group, triple vessel disease was significantly higher as compared with no vessel disease, single vessel disease, and control group (p<0.05). We could not find any significant differences in t-PA values between CAD patients and control group. On the other hand, the average leptin levels in the group of patients were higher than those in the control group but there were no statistically significant differences found between them (p>0.05) because of high SD values. There was strong (+) correlation between fibronectin, vitronectin, and severity of disease [vitronectin/severity of disease, r = 0.5074 (p = 0.000), fibronectin/severity of disease, r = 0.2971 (p = 0.007)]. In conclusion, we can say that fibronectin and vitronectin have become greatly important in pathogenesis of coronary artery disease. High leptin levels may be contribute to platelet aggregation in patients with coronary artery disease. But, elevated serum levels of leptin cannot be useful diagnostic and monitoring markers in patients with coronary artery disease.
authors.affiliation: Department of Biochemistry, Cerrahpasa Medical Faculty, University of Istanbul, Turkey. hakekmekci@yahoo.com
authors.forename: Hakan
authors.initials: H
authors.lastname: Ekmekci
authors.forename: Ozlem B
authors.initials: OB
authors.lastname: Ekmekci
authors.forename: Huseyin
authors.initials: H
authors.lastname: Sonmez
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Ozturk
authors.forename: Nergiz
authors.initials: N
authors.lastname: Domanic
authors.forename: Emine
authors.initials: E
authors.lastname: Kokoglu
mesh_terms: D000328:Adult; D000368:Aged; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000097:blood*; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000097:blood; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012907:Smoking; D013927:Thrombosis / Q000097:blood*; D010959:Tissue Plasminogen Activator / Q000097:blood; D019096:Vitronectin / Q000097:blood*
chemical_list: D005353:Fibronectins; D020738:Leptin; D019096:Vitronectin; D002784:Cholesterol; D010959:Tissue Plasminogen Activator